- Full Year 2023 MorphoSys AG Earnings Call TranscriptMar 14, 2024$17.94 (-0.55%)Earnings
- MorphoSys AG to be Acquired by Novartis AG Call TranscriptFeb 06, 2024
- MorphoSys AG at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- MorphoSys AG at ASH Meeting and Exposition TranscriptDec 11, 2023
- MorphoSys AG to Discuss MANIFEST-2 Results TranscriptNov 21, 2023
- Q3 2023 MorphoSys AG Earnings Call TranscriptNov 16, 2023$6.2 (-10.79%)Earnings
- MorphoSys AG at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Half Year 2023 MorphoSys AG Earnings Call TranscriptAug 10, 2023$7.54 (+0.53%)Earnings
- MorphoSys AG Investor Call Focused on Pelabresib TranscriptJun 21, 2023
- MorphoSys AG at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Q1 2023 MorphoSys AG Earnings Call TranscriptMay 04, 2023$5.56 (+7.96%)Earnings
- Full Year 2022 MorphoSys AG Earnings Call TranscriptMar 16, 2023$3.93 (+5.08%)Earnings
- MorphoSys AG at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Q3 2022 MorphoSys AG Earnings Call TranscriptNov 17, 2022$3.99 (+3.37%)Earnings
- MorphoSys AG at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Q2 2022 MorphoSys AG Earnings Call TranscriptAug 04, 2022$5.68 (-2.07%)Earnings
- MorphoSys AG at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 MorphoSys AG Earnings Call TranscriptMay 05, 2022$5.16 (-4.62%)Earnings
- Full Year 2021 MorphoSys AG Earnings Call TranscriptMar 17, 2022$6.83 (+1.94%)Earnings
- MorphoSys AG at JPMorgan Healthcare Conference TranscriptJan 12, 2022
- Q3 2021 MorphoSys AG Earnings Call TranscriptNov 11, 2021$10.81 (-1.91%)Earnings
- MorphoSys AG at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- MorphoSys AG at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2021
- Half Year 2021 MorphoSys AG Earnings Call TranscriptJul 29, 2021$13.99 (+1.52%)Earnings
- MorphoSys AG To Acquire Constellation Pharmaceuticals M&A Call TranscriptJun 02, 2021
- MorphoSys AG at UBS Global Healthcare Virtual Conference TranscriptMay 25, 2021
- Q1 2021 MorphoSys AG Earnings Call TranscriptMay 06, 2021$22.09 (+2.60%)Earnings
- Full Year 2020 MorphoSys AG Earnings Call TranscriptMar 16, 2021$22.76 (-10.22%)Earnings
- MorphoSys AG at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Q3 2020 MorphoSys AG Earnings Call TranscriptNov 12, 2020$25.78 (-2.61%)Earnings
- MorphoSys AG and Incyte Corp to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas Investor Call TranscriptSep 29, 2020
- Half Year 2020 MorphoSys AG Earnings Call TranscriptAug 06, 2020$32.67 (-5.96%)Earnings
- MorphoSys AG at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- Q1 2020 MorphoSys AG Earnings Call TranscriptMay 07, 2020$30.15 (+10.32%)Earnings
- Full Year 2019 MorphoSys AG Earnings Call TranscriptMar 19, 2020$19.67 (+4.29%)Earnings
- MorphoSys AG at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- MorphoSys AG and Incyte Sign Global Collaboration and License Agreement for Tafasitamab Conference Call TranscriptJan 13, 2020
- Q3 2019 Morphosys AG Earnings Call TranscriptOct 30, 2019$27.64 (+0.84%)Earnings
- Half Year 2019 Morphosys AG Earnings Call TranscriptAug 07, 2019$30.41 (+4.68%)Earnings
- Morphosys AG To Discuss Results From The Primary Analysis Of The Ongoing Single-Arm Phase 2 Clinical Trial L-MIND Conference Call TranscriptMay 20, 2019
- Q1 2019 Morphosys AG Earnings Call TranscriptMay 08, 2019$26.52 (+6.81%)Earnings
- Full Year 2018 Morphosys AG Earnings Call TranscriptMar 14, 2019$24.33 (-0.69%)Earnings
MorphoSys AG at JPMorgan Healthcare Conference Transcript
Great. Good afternoon. I'm James Gordon, JPMorgan European Pharma and Biotech Analyst. And today, I've got the pleasure of introducing the MorphoSys presentation. And you're going to hear from MorphoSys CEO Jean-Paul Kress.
Thanks very much for joining us today. Looking forward to the presentation.
Thank you, James. Thanks for having me and very pleased to share with you the great progress we're making at MorphoSys. Please have a look at our forward-looking statement slide.
A few years ago, we redefined the strategy of the company, and we centered on oncology and more specifically, hematology oncology. And for that, we beefed up our pipeline with the acquisition of Constellation and mainly pelabresib, which is our number one opportunity. Pelabresib is a BET inhibitor, which has the potential to redefine the standard of care in myelofibrosis first line and establish a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)